These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Woolley DE; Tetlow LC Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391 [TBL] [Abstract][Full Text] [Related]
7. Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. Conti P; Lessiani G; Kritas SK; Ronconi G; Caraffa A; Theoharides TC Tissue Cell; 2017 Jun; 49(3):393-400. PubMed ID: 28420489 [TBL] [Abstract][Full Text] [Related]
8. Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. Conti P; Ronconi G; Kritas SK; Caraffa A; Theoharides TC Can J Diabetes; 2018 Oct; 42(5):568-573. PubMed ID: 29885882 [TBL] [Abstract][Full Text] [Related]
9. Mast cell in innate immunity mediated by proinflammatory and antiinflammatory IL-1 family members. Robuffo I; Toniato E; Tettamanti L; Mastrangelo F; Ronconi G; Frydas I; Caraffa Al; Kritas SK; Conti P J Biol Regul Homeost Agents; 2017; 31(4):837-842. PubMed ID: 29254286 [TBL] [Abstract][Full Text] [Related]
10. IL-10 in Mast Cell-Mediated Immune Responses: Anti-Inflammatory and Proinflammatory Roles. Nagata K; Nishiyama C Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067047 [TBL] [Abstract][Full Text] [Related]
11. Mast cell and cancer with special emphasis on il-37 an anti-inflammatory and inhibitor of innate immunity: new frontiers. Carinci F; Lessiani G; Spinas E; Kritas SK; Ronconi G; Caraffa Al; Conti P J Biol Regul Homeost Agents; 2016; 30(4):945-950. PubMed ID: 28078840 [TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. Conti P; Carinci F; Lessiani G; Spinas E; Kritas SK; Ronconi G; Caraffa A; Theoharides TC Immunol Res; 2017 Oct; 65(5):982-986. PubMed ID: 28748328 [TBL] [Abstract][Full Text] [Related]
13. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells. Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074 [TBL] [Abstract][Full Text] [Related]
15. In activated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. Hültner L; Kölsch S; Stassen M; Kaspers U; Kremer JP; Mailhammer R; Moeller J; Broszeit H; Schmitt E J Immunol; 2000 Jun; 164(11):5556-63. PubMed ID: 10820229 [TBL] [Abstract][Full Text] [Related]
16. WZ3146 inhibits mast cell Lyn and Fyn to reduce IgE-mediated allergic responses in vitro and in vivo. Park YH; Kim DK; Kim HS; Lee D; Lee MB; Min KY; Jo MG; Lee JE; Kim YM; Choi WS Toxicol Appl Pharmacol; 2019 Nov; 383():114763. PubMed ID: 31526816 [TBL] [Abstract][Full Text] [Related]